Table 2.
Final adjusted multivariable linear mixed effects models of child and adult combined measures (N=1615 patients; N=6559 observations)
| Measure | β (95% CI) | P |
|---|---|---|
| Child + adult: fatigue | ||
| Age (per yr) | –0.12 (–0.15, –0.09) | <0.001 |
| Male vs. female | 2.80 (1.74, 3.85) | <0.001 |
| SES (college education vs. none) | 1.79 (0.73, 2.85) | 0.001 |
| Edema (any vs. none) | –2.93 (–3.59, –2.28) | <0.001 |
| Number of symptoms (per symptom) | –0.87 (–1.09, –0.66) | <0.001 |
| Weight | 0.002 | |
| Underweight | 0.58 (–1.84, 3.00) | 0.64 |
| Overweight | –1.17 (–2.10, –0.23) | 0.01 |
| Obese | –2.04 (–3.09, –0.99) | <0.001 |
| Normal | Ref | |
| eGFR (per 30 ml/min per 1.73 m2) | 0.52 (0.13, 0.91) | 0.01 |
| Number of medications (per medication) | –0.26 (–0.38, –0.14) | <0.001 |
| Exposed to CTX | –2.59 (–4.91, –0.27) | 0.03 |
| Time (per year) | 1.01 (0.65, 1.37) | <0.001 |
| Child + adult: anxiety | ||
| Age (per yr) | –0.10 (–0.12, –0.09) | <0.001 |
| Male vs. female | 2.00 (1.40, 2.61) | <0.001 |
| Edema (any vs. none) | –1.71 (–2.11, –1.32) | <0.001 |
| Number of symptoms (per symptom) | –0.40 (–0.53, –0.28) | <0.001 |
| Time (per yr) | 0.36 (0.16, 0.57) | <0.001 |
CI, confidence interval; CTX, Cytoxan (cyclophosphamide); eGFR, estimated glomerular filtration rate; Ref, referent; SES, socioeconomic status.
For each domain, scores have been transformed so higher scores indicate better health-related quality of life.